Skip to content

News

Rosalind Franklin Excellence in Ovarian Cancer Research Award

Rosalind Franklin Excellence in Ovarian Cancer Research Award

Introducing the 2015 Ovarian Cancer National Conference Rosalind Franklin Excellence in Ovarian Cancer Research Award winner: Beth Karlan, MD. The Rosalind Franklin Excellence in Ovarian Cancer Research Award is named for the molecular biologist Dr. Rosalind Elsie Franklin, who played a vital role in discovering the structure of DNA. Her career was cut short in 1958 when she died of ovarian cancer at age 37. Throughout her life, she was a committed researcher; this award honors an individual who continues her legacy of excellence. Beth Karlan, MD is the Director of the Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, and Director of the Gilda Radner Hereditary Cancer Program. Click the plus sign to read more.

OCRA News

Cindy Melancon Spirit Award

Cindy Melancon Spirit Award

The Cindy Melancon Spirit Award commends and honors an individual for his or her commitment to the ovarian cancer community. The award is named after Cindy Melancon, a founder of the Ovarian Cancer National Alliance and creator of the CONVERSATIONS! newsletter. The award has been given to many excellent ovarian cancer leaders throughout the years. Carey Fitzmaurice, survivor since 2006, is the founder of Teal Toes, a national non-profit organization dedicated to educating women about the symptoms of ovarian cancer. Since 2007, Teal Toes has been sending out symptom cards, and promoting education and awareness through its website and social media. Click the plus sign to read more.

Community

AACR Update

AACR Update

Research Advocate Seana Roubinek attended the 2015 American Association of Cancer Research Annual Meeting in April.  Here is her report:  “As a two-time cancer ovarian cancer survivor, I have had … Continued

Advocacy

ACA Update

ACA Update

New Affordable Care Act guidance says women with ovarian cancer can receive free genetic counseling, testing. On May 11, 2015, the U.S. Department of Health and Human Services, Labor and Treasury issued new guidance to clarify services and coverage available under the Affordable Care Act. Before today, only women with a family history of ovarian and breast cancer were eligible for genetic testing and counseling free from additional out-of-pocket expense. Click the plus sign to read on...

Advocacy

New Screening Approach Shows Promise

New Screening Approach Shows Promise

(May 5, 2015) Data from a large clinical trial shows that a personalized method for interpreting blood tests identifies more ovarian cancer cases than a generalized approach. The results from … Continued

Research

Drug Recall

Drug Recall

On April 23, the drug manufacturer Mylan N.V. announced a voluntary nationwide recall of select lots of several drugs used in the treatment of ovarian cancer. The nationwide recall includes several formulations of injectable gemcitabine and cytarabine. While no adverse events have been reported with the use of these drugs, patients who may be experiencing problems related to these drugs should contact their physicians. Expand the post for more information about the recall.

Research

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.